Alethea Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Alethea Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-7,315	Closed	-$425K	–	37
2023 Q3	$425K	Buy	+7,315	New	+$448K	0.52%	17
2023 Q2	–	Sell	-8,965	Closed	-$621K	–	56
2023 Q1	$621K	Buy	+8,965	New	+$632K	0.66%	17
2020 Q4	–	Sell	-10,487	Closed	-$632K	–	76
2020 Q3	$632K	Sell	10,487 -15,306	-59%	-$921K	0.43%	31
2020 Q2	$1.52M	Buy	25,793 +4,571	+22%	+$273K	0.89%	8
2020 Q1	$1.18M	Buy	+21,222	New	+$1.3M	0.77%	11
2019 Q1	–	Sell	-26,873	Closed	-$1.4M	–	78
2018 Q4	$1.4M	Buy	+26,873	New	+$1.44M	2.03%	12
2018 Q2	–	Sell	-7,752	Closed	-$490K	–	68
2018 Q1	$490K	Buy	+7,752	New	+$499K	0.66%	40
2017 Q3	–	Sell	-27,038	Closed	-$1.51M	–	79
2017 Q2	$1.51M	Buy	+27,038	New	+$1.47M	1.71%	20
2017 Q1	–	Sell	-27,392	Closed	-$1.6M	–	77
2016 Q4	$1.6M	Buy	27,392 +11,109	+68%	+$607K	2.02%	17
2016 Q3	$878K	Buy	+16,283	New	+$1.05M	1.22%	28
2015 Q4	–	Sell	-8,190	Closed	-$485K	–	70
2015 Q3	$485K	Sell	8,190 -2,025	-20%	-$128K	0.74%	33
2015 Q2	$680K	Buy	+10,215	New	+$673K	1.04%	20

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Alethea Capital Management's BMY Position: Q4 2023 in Review

Alethea Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 7,315 shares — an estimated $425K sold.

Alethea Capital Management first reported a position in BMY in Q2 2015 and held it in 12 quarters. The position peaked at $1.6M in Q4 2016. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Alethea Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Alethea Capital Management sold 7,315 Bristol-Myers Squibb shares in Q4 2023, an estimated $425K.
Alethea Capital Management first reported a position in Bristol-Myers Squibb in Q2 2015 and held it in 12 quarters.
Alethea Capital Management's Bristol-Myers Squibb position peaked at $1.6M in Q4 2016.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Alethea Capital Management's 13F filing for Q4 2023, filed 15 Feb 2024.